tradingkey.logo

Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnP

ReutersDec 23, 2025 1:12 PM

- Immuneering Corp IMRX.O:

  • IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON JANUARY 7, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI